Sera Prognostics Q3 2026 Results: Net Loss of $8.05M, Loss Widens
Sera Prognostics, Inc. reported its financial results for the quarter ended September 30, 2026, highlighting continued commercialization efforts for its PreTRM test. The company maintained a strong cash position while focusing on expanding clinical evidence and market adoption to drive long-term growth.
- Key figure
- Net loss $8.05M